Ionis Announces Submission of Marketing Authorization Application for Inotersen to the EMA Post author:Sam Post published:November 2, 2017 Post category:BioPharma The MAA will be reviewed under the EMA’s Accelerated Assessment program. Source: BioSpace You Might Also Like Little reMYND Forges 350M+ Euros Tie-Up With Drug Giant Novo Nordisk December 13, 2017 New Jersey Startup Launches With Clinical Assets From Big Name Biotechs August 21, 2017 Exelixis Announces Second Quarter 2017 Financial Results And Provides Corporate Update August 2, 2017
Exelixis Announces Second Quarter 2017 Financial Results And Provides Corporate Update August 2, 2017
